Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...
On Friday, Prime Medicine Inc (PRME) stock saw a decline, ending the day at $3.46 which represents a decrease of $-0.10 or -2.81% from the prior close of $3.56. The stock opened at $3.62 and touched a ...
Some results have been hidden because they may be inaccessible to you